Equities Analysts Offer Predictions for Aemetis, Inc.’s FY2023 Earnings (NASDAQ:AMTX)


Share on StockTwits

Aemetis, Inc. (NASDAQ:AMTX) – Truist Securiti upped their FY2023 EPS estimates for shares of Aemetis in a research note issued on Wednesday, April 7th. Truist Securiti analyst J. Levy now expects that the specialty chemicals company will earn $0.89 per share for the year, up from their prior estimate of $0.80. Truist Securiti also issued estimates for Aemetis’ FY2024 earnings at $3.68 EPS and FY2025 earnings at $6.54 EPS.

A number of other analysts have also weighed in on the stock. Truist Financial began coverage on shares of Aemetis in a research note on Friday, March 19th. They issued a “buy” rating for the company. Zacks Investment Research lowered shares of Aemetis from a “hold” rating to a “sell” rating in a research report on Tuesday, March 16th. HC Wainwright increased their price target on shares of Aemetis from $15.00 to $28.00 in a research report on Monday, March 15th. Credit Suisse Group began coverage on shares of Aemetis in a research report on Monday, March 29th. They set an “outperform” rating and a $35.00 price target for the company. Finally, Stifel Nicolaus assumed coverage on shares of Aemetis in a research report on Monday, March 15th. They set a “buy” rating and a $25.00 price target for the company. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. Aemetis presently has an average rating of “Buy” and an average price target of $31.60.

NASDAQ:AMTX opened at $24.70 on Thursday. Aemetis has a 1-year low of $0.53 and a 1-year high of $27.44. The company has a 50-day moving average of $17.30 and a 200 day moving average of $7.12. The firm has a market cap of $669.35 million, a PE ratio of -17.64 and a beta of 0.09.

Aemetis (NASDAQ:AMTX) last released its quarterly earnings data on Monday, March 15th. The specialty chemicals company reported ($0.68) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.10). The company had revenue of $37.33 million for the quarter, compared to the consensus estimate of $47.34 million.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in shares of Aemetis during the third quarter valued at about $85,000. HighPoint Advisor Group LLC acquired a new position in Aemetis in the 4th quarter worth approximately $197,000. Hussman Strategic Advisors Inc. acquired a new position in Aemetis in the 4th quarter worth approximately $76,000. Finally, Renaissance Technologies LLC increased its holdings in Aemetis by 57.2% in the 4th quarter. Renaissance Technologies LLC now owns 1,731,349 shares of the specialty chemicals company’s stock worth $4,311,000 after buying an additional 629,721 shares during the period. Hedge funds and other institutional investors own 12.89% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable fuels and bio-chemicals company in North America and India. The company focuses on the acquisition, development, and commercialization of various technologies that replace traditional petroleum-based products primarily through the conversion of ethanol and biodiesel plants into advanced bio refineries.

Recommended Story: What’s a Black Swan?

Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.